Literature DB >> 20647822

Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc.

Raffaella Rossi, Miriam Lichtner, Ilaria Sauzullo, Fabio Mengoni, Raffaella Marocco, Anna Paola Massetti, Claudio Maria Mastroianni, Vincenzo Vullo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20647822     DOI： 10.1097/QAI.0b013e3181ed18f6

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  8 in total

1.  Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.

Authors:  Ivana Massud; Wutyi Aung; Amy Martin; Shanon Bachman; James Mitchell; Rachael Aubert; Theodros Solomon Tsegaye; Ellen Kersh; Chou-Pong Pau; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

2.  In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.

Authors:  R Rossi; M Lichtner; A De Rosa; I Sauzullo; F Mengoni; A P Massetti; C M Mastroianni; V Vullo
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 3.  CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.

Authors:  Guillaume Martin-Blondel; David Brassat; Jan Bauer; Hans Lassmann; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

4.  Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.

Authors:  Michelle L D'Antoni; Brooks I Mitchell; Sara McCurdy; Mary Margaret Byron; Debra Ogata-Arakaki; Dominic Chow; Nehal N Mehta; William A Boisvert; Eric Lefebvre; Cecilia M Shikuma; Lishomwa C Ndhlovu; Yvonne Baumer
Journal:  J Leukoc Biol       Date:  2018-08-08       Impact factor: 4.962

5.  Effect of maraviroc on HIV disease progression-related biomarkers.

Authors:  M Concepción Romero-Sánchez; Kawthar Machmach; Alejandro Gonzalez-Serna; Miguel Genebat; Ildefonso Pulido; María García-García; Ana Isabel Alvarez-Ríos; Sara Ferrando-Martinez; Ezequiel Ruiz-Mateos; Manuel Leal
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

6.  Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).

Authors:  Lishomwa C Ndhlovu; Tracie Umaki; Glen M Chew; Dominic C Chow; Melissa Agsalda; Kalpana J Kallianpur; Robert Paul; Guangxiang Zhang; Erika Ho; Nancy Hanks; Beau Nakamoto; Bruce T Shiramizu; Cecilia M Shikuma
Journal:  J Neurovirol       Date:  2014-09-17       Impact factor: 2.643

7.  In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.

Authors:  Pasqua Gramegna; Tiziana Latronico; Maria Teresa Branà; Gaetano Di Bari; Fabio Mengoni; Valeria Belvisi; Maria T Mascellino; Miriam Lichtner; Vincenzo Vullo; Claudio M Mastroianni; Grazia M Liuzzi
Journal:  PLoS One       Date:  2011-12-08       Impact factor: 3.240

8.  HIV-1 induces cytoskeletal alterations and Rac1 activation during monocyte-blood-brain barrier interactions: modulatory role of CCR5.

Authors:  Shawna M Woollard; Hong Li; Sangya Singh; Fang Yu; Georgette D Kanmogne
Journal:  Retrovirology       Date:  2014-02-26       Impact factor: 4.602
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.